Joint Clinical Assessment for Medical Devices: The First Selections Have Begun

The EU joint clinical assessment is no longer only about medicines. Procedural rules for medical devices and in vitro diagnostics are now in place, and the Commission has reportedly adopted its first decision selecting devices for assessment, which makes JCA a launch-planning issue for device manufacturers.

The procedural rules

Commission Implementing Regulation (EU) 2025/2086, adopted in October 2025, sets out how the Member State Coordination Group, the Commission, notified bodies, expert panels and developers interact when JCAs of devices and IVDs are prepared and updated. It covers expert selection and conflict-of-interest screening, stakeholder input, scoping, dossier submission, report finalisation, updates, and publication, and it provides templates for dossiers and reports.

How devices enter the pool

Selection draws on devices for which an MDR expert panel has issued a clinical evaluation consultation opinion, or IVDs for which an expert panel has given views under IVDR Article 48(6). Selection under the HTA Regulation uses criteria such as unmet medical need, first-in-class status, potential impact on patients or health systems, the use of artificial intelligence, cross-border dimension and Union-wide added value. Secondary reporting indicates the first selection decision was adopted on 2 October 2026 and covered two cardiovascular valve replacement systems, but manufacturers should read the Commission text itself.

What happens after selection

Reported timelines indicate that the developer receives the assessment scope and a request for the dossier, and has 100 days to deliver it, followed by a Commission completeness check. The implementing regulation sets a finalisation deadline of 165 days for reports, extended to 345 days where the scope must be updated. As with medicines, the report is a scientific analysis and does not decide pricing or reimbursement, which remain national.

What manufacturers should do now

  • Check whether the product is likely to go through expert panel review.
  • Treat a possible JCA as part of launch planning, with clinical evidence designed for a Union-level comparison.
  • Align the JCA dossier with the clinical evaluation and PMCF plan so claims and data are consistent.
  • Prepare national reimbursement strategy in parallel, including for Greece.

How PQRA helps

PQRA helps device manufacturers assess JCA exposure, align clinical evidence with expert panel and HTA expectations, and plan reimbursement in Greece alongside the EU process.

Launching a high-risk device in the EU? Contact PQRA for a practical discussion.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *